Coherus Oncology, Inc. (CHRS) Free cash flow 2016–2023
Coherus Oncology, Inc. (CHRS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$175.2MFY2023 · since FY2016: -$259.1M → -$175.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$175.2M | +28.0% |
| FY2022 | -$243.2M | -528.0% |
| FY2021 | -$38.7M | -126.4% |
| FY2020 | $146.9M | +453.7% |
| FY2019 | $26.5M | +116.6% |
| FY2018 | -$160.1M | +21.9% |
| FY2017 | -$204.9M | +20.9% |
| FY2016 | -$259.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →